When was T2 Biosystems founded?

T2 Biosystems was founded in 2006 and raised its 1st funding round within a year of its incorporation.

Where is T2 Biosystems located?

T2 Biosystems is headquartered in Lexington, United States. It is registered at Lexington, Massachusetts.

How many employees does T2 Biosystems have?

As of Feb 28, 2026, the latest employee count at T2 Biosystems is 56.

Is T2 Biosystems a funded company?

T2 Biosystems is a funded company, having raised a total of $454M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 01, 2006.

When was the latest funding round of T2 Biosystems?

T2 Biosystems' latest funding was a $***** Grant (prize money) round on Mar 06, 2018, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $210M in funding in 2026 to date.

What is the annual revenue of T2 Biosystems?

Annual revenue of T2 Biosystems is $7.19M as on Dec 31, 2023.

Where does T2 Biosystems rank among its competitors?

T2 Biosystems ranks 10th amongst 329 active competitors, of which 80 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was HaystackAnalytics, which secured $4.28M in Sep, 2025.

Who are the top competitors of T2 Biosystems?

T2 Biosystems' top competitors include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Among them, HaystackAnalytics secured the most recent funding round in September, 2025.

T2 Biosystems - 2026 Company Profile, Team, Funding, Competitors & Financials

T2 Biosystems is a public company based in Lexington (United States), founded in 2006. It operates as a Developer of miniaturized MRI platforms for clinical diagnostics. T2 Biosystems has raised $454M in funding from investors like Polaris Partners, Flybridge Capital Partners and Flagship Pioneering. The company has 329 active competitors, including 80 funded and 48 that have exited. Its top competitors include companies like Adaptive Biotechnologies, MeMed and HaystackAnalytics.

Company Details

Developer of miniaturized MRI platforms for clinical diagnostics. The proprietary platform T2MR uses miniaturized MRIs to detect pathogens by measuring reaction changes for water molecules in the presence of magnetic fields. Also, the company has panels for bacterial septic infections, hemostasis, and Lyme disease in the pipeline.

Website: www.t2biosystems.com
Social
Email ID: *****@t2biosystems.com
Phone Number: +1 **********
Registered Address: Lexington, Massachusetts

Key Metrics

Founded Year

2006

Location

Lexington, United States

Stage

Public

Total Funding

$454M in 11 rounds

Latest Funding Round

Grant (prize money), Mar 06, 2018, $*****

Investors

Polaris Partners & 21 more

Ranked

10^th among 329 active competitors

Annual Revenue

$7.19M as on Dec 31, 2023

Employee Count

56 as on Feb 28, 2026

Similar Companies

Adaptive Biotechnologies & 399 more

Exit Details

Public

View T2 Biosystems' full profile

T2 Biosystems is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
T2 BIOSYSTEMS, INC. CIN: 1492674 , United States, Active	May 27, 2010	$7.19M (As on Dec 31, 2023)	-	-
T2 BIOSYSTEMS INC CIN: 204827488 , United States, Active	Dec 31, 1999	-	90 (As on Dec 31, 2024)	-

T2 Biosystems got listed on Aug 08, 2014.

Click here to take a look at T2 Biosystems's IPO in detail

T2 Biosystems has raised a total funding of $454M over 11 rounds. Its first funding round was on Jan 01, 2006. Its latest funding round was a Grant (prize money) round on Mar 06, 2018 for $*****. 1 investor participated in its latest round. T2 Biosystems has 22 institutional investors.

Here is the list of recent funding rounds of T2 Biosystems:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 06, 2018	4875106	Grant (prize money)	9924148	7399536	7650766	9996795
Jan 05, 2017	4056232	Conventional Debt	3684452	6057251	1530158	CRG
Sep 27, 2016	3472585	Post IPO	4183646	9978793	3576372	Canon

Access funding benchmarks and valuations. Sign up today!

View details of T2 Biosystems's funding rounds and investors

T2 Biosystems' employee count trend

T2 Biosystems has 56 employees as of Feb 26. Here is T2 Biosystems's employee count trend over the years:

Uncover T2 Biosystems' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T2 Biosystems include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of T2 Biosystems, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	68/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$16.6M	SINE, Sun Pharma & 31 others	67/100
4th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	64/100
5th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
6th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	57/100
7th	Seegene Technologies 2000, Seoul (South Korea), Acquired	Developer of molecular diagnostic kits to detect infectious and genetic diseases	-	IMM Investment, Songhyun Investment & 3 others	57/100
8th	DeepUll 2020, Barcelona (Spain), Series C	Developer of diagnostic solutions for sepsis and acute infections	$92.5M	Columbus Venture Partners, Panakes Partners ... & 14 others	56/100
9th	Quantamatrix 2010, Seoul (South Korea), Public	Multiplexed platform for disease daignosis	$198K	Treatment Action Group, Korea Omega Investment Corp ... & 6 others	55/100
10th	T2 Biosystems 2006, Lexington (United States), Public	Developer of miniaturized MRI platforms for clinical diagnostics	$454M	Aisling Capital, Goldman Sachs & 20 others	55/100